Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Assets: 2015-2024

Historic Current Assets for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to $639.9 million.

  • Intellia Therapeutics' Current Assets fell 18.14% to $581.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $581.9 million, marking a year-over-year decrease of 18.14%. This contributed to the annual value of $639.9 million for FY2024, which is 35.91% down from last year.
  • Intellia Therapeutics' Current Assets amounted to $639.9 million in FY2024, which was down 35.91% from $998.3 million recorded in FY2023.
  • In the past 5 years, Intellia Therapeutics' Current Assets ranged from a high of $1.2 billion in FY2022 and a low of $616.5 million during FY2020.
  • In the last 3 years, Intellia Therapeutics' Current Assets had a median value of $998.3 million in 2023 and averaged $951.7 million.
  • In the last 5 years, Intellia Therapeutics' Current Assets surged by 112.97% in 2020 and then slumped by 35.91% in 2024.
  • Over the past 5 years, Intellia Therapeutics' Current Assets (Yearly) stood at $616.5 million in 2020, then grew by 24.78% to $769.3 million in 2021, then surged by 58.17% to $1.2 billion in 2022, then dropped by 17.95% to $998.3 million in 2023, then slumped by 35.91% to $639.9 million in 2024.